NCT03742921已完成不适用
ISTODAX® for Intravenous Infusion 10mg Drug Use Results Survey - Relapsed or Refractory Peripheral T-Cell Lymphoma
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Celgene
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Adverse Events (AEs)
研究概览
简要总结
To ascertain the safety and efficacy of Istodax® in actual clinical settings in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who receive Istodax.
- Planned registration period 4 years
- Planned surveillance period 5 years and 6 months
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who have been diagnosed with relapsed or refractory PTCL who receive Istodax for the first time.
排除标准
- 未提供
研究组 & 干预措施
Relapsed or Refractory T-Cell Lymphoma patients with Istodax
Among patients with relapsed or refractory peripheral T-Cell lymphoma, patients who received Istodax will be targeted in this surveillance
干预措施: Istodax (Drug)
结局指标
主要结局
Adverse Events (AEs)
时间窗: Up to approximately 5 years
Number of participants with adverse event
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo.Overactive BladderNCT00479596Urological Sciences Research Foundation40
已完成
2 期
Study of Clinical Efficacy and Safety of Tosedostat in MDSMyelodysplastic SyndromeNCT02452346Weill Medical College of Cornell University12
已完成
不适用
Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) StudyUnresectable Hepatocellular CarcinomaNCT05667064AstraZeneca1,200
撤回
2 期
Safety and Efficacy Study of Istaroxime in Acute Decompensated Heart Failure PatientsHeart FailureNCT00838253Debiopharm International SA
尚未招募
4 期
Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and AnemiaAnemiaChronic Kidney DiseasesHeart FailureNCT05691257China-Japan Friendship Hospital300